BAYLOR COLLEGE OF MEDICINE
Mouse models of caspase-2 deficient nucleophosmin-mutated AML
Mouse models of caspase-2 deficient nucleophosmin-mutated AML is a funding opportunity from BAYLOR COLLEGE OF MEDICINE, up to 160500, closing June 30, 2027.
Jun 30, 2027
(334d left)Overview
SUMMARY Prognosis for relapsed acute myeloid leukemia (AML) is dismal (50% relapse rate, 5-year overall survival less than 28%), underscoring the critical need for more effective, less toxic therapies. The most frequently mutated gene in AML is nucleophosmin (NPM1). Mutations in NPM1 (NPM1c+) are leukemia-generating…